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Abstract
Purpose Many physicians express a relatively nihilistic
approach to the treatment of hepatocellular carcinoma
(HCC) with portal vein tumor thrombus (PVTT). Consensus
among surgeons regarding the indications for an aggressive
approach has not been reached. Current study was aimed to
determine whether an aggressive approach, with an extended
resection with thrombectomy and adjuvant therapy, would
lead to an improved survival for HCC patients with PVTT.
Methods A retrospective review of 116 HCC patients
with PVTT admitted from 1996 to 2006 was conducted.
Patients were divided into 2 time-period (TP) cohorts, of
them, 51 cases in the first 5 years (TP1) and 65 in the last
5 years (TP2).
Results Surgical operations were performed on 68 patients.
Twenty-one surgical resections were performed in TP1 and
forty-seven in TP2. The extent of liver resections, as well as
the frequency of thrombectomy, was greater in TP2
(P = 0.039). During both time-periods, an aggressive ther-
apy was associated with improved survival (P \ 0.02 TP1,
P \ 0.001 TP2). Overall survival of all patients in TP2 was
significantly greater than in TP1 (P \ 0.001), with a median
survival of 15 months in TP2, whereas in TP1, the survival
was only 9 months. The median 1-, 3-year survivals in TP2
(54 and 34%, respectively) were also greater than that in TP1
(31 and 7%, respectively). A multiple logistic regression
analysis revealed that radical resection and adjuvant therapy
were the independent predictors of overall survival.
Conclusions An aggressive approach, combining exten-
ded liver resection with thrombectomy and adjuvant ther-
apy, leads to an improved survival in the HCC patients
with PVTT.
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Introduction
Hepatocellular carcinomas (HCC) are commonly devel-
oped secondary to patients with hepatitis B and C in both
Africa and Asia. Recently, an increasing incidence of HCC
was also reported in Western countries (El-Serag and
Mason 1999). The natural history of untreated HCC is
poor, especially in patients with portal vein tumor throm-
bus (PVTT), with a median survival of 2.7 months,
whereas the survival in those without PVTT was
24.4 months (Llovet et al. 1999b). The involvement of
PVTT in main portal trunk could result in portal hyper-
tension, which would further lead to gastrointestinal
bleeding, ascites, and induce multiple intrahepatic tumor
dissemination and recurrence (Nagasue et al. 2001; Roa-
yaie et al. 2002; Poon et al. 2003). The treatment of HCC
with PVTT is still considered as nihilism and remains a
major challenge due to poor survival rates (Poon et al.
2002; Bruix and Llovet 2002; Lee et al. 2002). However, it
should be noted that some patients actually survived for a
long period of time after a single tumor resection or
combined with neo- and/or adjuvant therapy (Yamaoka
et al. 1992; Minagawa et al. 2001; Masami et al. 2001;
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Aldrighetti et al. 2009). With the improvement of surgical
techniques and perioperative care, promising results have
also been achieved by using aggressive procedures to treat
HCC with PVTT (Minagawa et al. 2001).
At the turn of the millennium, a reappraisal of our
technical approach to HCC with PVTT was conducted at
Mindong Hospital, Fujian, China, and a more aggressive
treatment strategy has been adopted,which consists of
extended liver resection, thrombectomy, and neo- and/or
adjuvant therapy. In order to evaluate the outcomes of this
shift in the treatment to HCC patients, a 10-year retro-
spective review of all 116 HCC patients with PVTT
admitted between 1996 and 2006 has been conduced. The
results confirmed that surgical removal of the main tumor
and PVTT, combining with the neo- and/or adjuvant
therapy, significantly improved the survival of HCC
patients with PVTT.
Materials and methods
The records of all 116 individual patients diagnosed of
HCC with PVTT in Mindong Hospital, Fujian, China, were
included in current study. These records, including
patients’ inpatient hospital and clinic charts, covered the
cases of a 10-year period from January 1996 to August
2006. Of all 116 cases, two time-period-based cohorts were
divided according to the treatment strategy. A total of 51
patients admitted in the first 5 years (from January 1996 to
December 2000) were included in Time-Period 1 (TP1),
and the remaining 65 patients were included in Time-
Period 2 (TP2). Approval for chart review was obtained
from the institutional review board at MinDong Hospital,
FuJian, China. Surgical mortality was considered as death
occurring within 60 days of surgery. Morbidity including
minor complications required no intervention, while major
complications required intervention.
Preoperative assessment included medical history,
physical examination, and imaging studies, including
abdominal ultrasound (US), computed tomography, and
magnetic resonance cholangiopancreatography (MRCP).
Patients from both TPs (without exception) have been
undergone triphasic liver CT scan, color Doppler US, and
endoscopic examination in order to determine the size and
location of HCC and PVTT in portal vein and possible
complications of esophageal and cardiac varices. For
patients with severe varices of the esophagus, sclerotherapy
has been performed prior to the surgery in order to prevent
perioperative bleeding.
A surgical operation has been performed mainly based
on the volume of the future remnant liver as determined by
CT volumetry (Okamoto et al. 1984) and on the removable
liver volume, which was evaluated by indocyanine green
retention rate at 15 min (ICGR15) (Takasaki et al. 1980).
During the operation, an intraoperative US was conducted
to determine the size and location of HCC and PVTT and
the relationship between the tumor and the vascular system.
The plane of liver parenchymal transection has been
defined as well. It should be noted here that parenchymal
transection was performed by conventional forceps-frac-
ture method until 2003, when ultrasonic dissectors were
introduced during parenchymal division, which has been
proven to be able to decrease the bleeding during the
operation. Central venous pressure was maintained at 5 cm
H2O or less during the parenchymal transection phase. In
order to remove the PVTT, the thrombus was resected
together with the liver when the thrombus was confined
within the resected liver. In cases that the PVTT protruded
into the portal vein 1 to 2 cm beyond the resection line, the
tumor thrombi were removed through the opening of
the involved portal vein stump at the resection surface after
the tumors were resected. The hepatoduodenal ligament was
taped before the procedures and blocked when necessary.
In several occasions, the PVTT could not be taken out
completely from the opening of the portal vein stump at the
resection surface due to the extension of PVTT into the
main portal trunk and/or the opposite branch, the main
portal trunk was clamped, and a 1.5- to 2.0-cm longitudinal
incision was made at the anterior or right wall of the portal
trunk. The tumor thrombi were then under direct vision and
could be removed with ease. After the removal of HCC and
PVTT, another US was conducted to make certain that the
tumor thrombus and the impairment had been removed
completely.
Clinical follow-up after surgery including serum alfa
fetoprotein (AFP) and US has been scheduled every 4 to
6 weeks during the first postoperative year and at 3 month
intervals thereafter. Computed tomography or magnetic
resonance imaging was performed once intrahepatic
recurrence was suspected.
Adjuvant therapy included preoperative transcatheter
hepatic arterial chemoembolization (neo-adjuvant therapy)
and postoperative transcatheter hepatic arterial chemo-
embolization (adjuvant therapy). Chemotherapy regimen
was as follows: IFN-a (5 9 106 U) was administered
subcutaneously on days 1, 3, and 5 of each week for
4 weeks, and 5-FU (300 mg/m2) dispersed in lipiodol (10
to 20 ml) was then administered every 2 weeks for
4 weeks, followed by embolization using gelatin sponge
particles (Gelfoam; Guangzhou), until there was near
complete stasis of blood flow. This procedure was then
repeated at 1-month interval depending on a patient’s liver
function and response to treatment. As a result, the number
of chemotherapy cycles varied from 1 to 6.
140 J Cancer Res Clin Oncol (2011) 137:139–149
123
Definitions
Terminology with respect to liver resections in this paper
follows the guideline of the International Hepato-
Pancreatico-Biliary Association (IHPBA). Resections may
also be described by the Couinaud segments resected
(Couinaud 1994). Wedge resection denotes a nonanatomic,
nonsegmental resection of the liver surrounding the HCC
to a depth of 1 to 2 cm. The level of the PVTT (Vp)
detected in preoperative imaging (Japan 2003; Llovet et al.
1999a) and postoperative pathology was classified into four
categories: Vp1, PVTT in distal to second-order portal
branches; Vp2, PVTT in second-order branches; Vp3,
PVTT in first-order branches; and Vp4, PVTT in the main
trunk and/or extended into opposite branch (Kondo et al.
2009).
Statistics
Univariate comparisons of 2 time-period groups were made
with the Fisher’s exact test or v2 test for dichotomous
covariates, and the t test for continuous variables.
Numerical data are expressed as the mean value ± stan-
dard deviation (SD) unless otherwise indicated. Differ-
ences were considered significant when P = 0.05 or less.
Patient survival was calculated using the Kaplan–Meier
method, and the survival curves were compared using the
log-rank test. Cox proportional hazards regression model-
ing was used to assess the effect that independent covari-
ates had on the dependent variable survival. Logistic
regression modeling was performed to assess the impact of
the covariates on the presence or absence of complications.
All statistical analyses were performed using SPSS version
16.0 for Windows (SPSS, Chicago, Illinois, USA).
Results
Clinical data
Table 1 compares of the clinical data between two TPs.
There was no statistically significant difference between
the two TPs, except that there were a larger proportion of
patients with multiple of tumors in TP2 than in TP1. It
should be pointed out that the data required for the Table 1
MELD-Score calculation (serum bilirubin, INR, and serum
creatinine) were obtained on admission. Due to the fact that
majority of HCC patients with PVTT who suffered from
virus-related hepatitis and liver cirrhosis had poor liver
functions on admission, as indicated by a higher serum
bilirubin value and a corresponding higher MELD-Score
has been observed (Table 1). Upon admission, liver func-
tion improvement and anti-virus treatments have been
given to these patients with very poor liver function. These
liver functions were re-evaluated prior to the surgeries and
found to be improved remarkably with much lower serum
bilirubin values than the values obtained on admission
(Table 1). Since only serum bilirubin data were collected
1–2 prior to the surgeries, no corresponding MELD-Scores
were shown in Table 1. For patients with relatively good
liver function on admission, surgeries were performed 1–
2 days after the admission. Neo-adjuvant therapy was
performed in patients with good hepatic reserve and col-
lateral circulation around the portal trunk (9 in TP1 vs. 31
in TP2, P \ 0.001).
Disease stage
Figure 1 compares the distribution of patients by the level
of the PVTT (Vp) between 2 TPs. The majority of patients
(73.8% in TP1 and 72.3% in TP2) were diagnosed at Vp2
and Vp3. It is noticeable that more patients from TP2 were
diagnosed with higher Vp disease (52.3% Vp3 and Vp4)
than from TP 1 (18.3% Vp3 and Vp4), with P \ 0.001.
Definitive therapy
Types of surgical resection and the surgical and postopera-
tive data of the both cohorts are listed in Tables 2 and 3,
respectively. Of all the 116 patients, 48 patients had
advanced disease (Vp3, Vp4, multiple cancer, and/or distant
metastasis) and did not receive any surgery. Among the
remaining 68 patients, 58 patients were explored for a
potentially curative (R0) resection (18 in TP 1 and 40 in TP 2,
P = 0.005) and have undergone liver resection and throm-
bectomy. Another 10 patients had received palliative (R1)
operations (removal of the PVTT in the main portal trunk and
resection of the tumor simultaneous) for esophageal varices
and ascites. Two patients from TP1 and 15 from TP2 have
further undergone a concomitant other organ resection
(P = 0.043). The majorities of operations in TP2 were
hemihepatectomy or extended hemihepatectomy. The extent
of liver resections and the frequency of thrombectomy were
greater in TP2 than those in TP1 (P = 0.039).
Adjuvant therapy was received by patients with con-
firmed positive microscopic margins at the resection sur-
face after the operation, multiple liver cancer, and higher
Vp (Vp3 or Vp4). There were 52 patients received che-
motherapy, 9 from TP1, and 43 from TP2 (P \ 0.001).
Perioperative complications
The overall operative mortality was low in both TPs with
a total of 3 died (Table 3). One of the patients who had
chronic liver disease died of liver failure after extended
right hepatectomy. Another one died of massive upper
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gastrointestinal bleeding, and the last one died of heart
failure. On the contrary, the complication rate among all
the operative patients was relatively high. Complications
included pleural effusion (12%), wound infection (9%),
liver failure (6%), upper GI bleed (5%), pneumonia (4%),
intraabdominal abscess (3%), Cardiac failure/ arrhythmia
(2%), postoperative bowel obstruction (2%), bile leak
(1%), DVT/pulmonary embolus (1%), and renal failure
(1%). None of the patients received reoperation. Two
patients developed intraabdominal abscesses requiring
percutaneous drainage. Multivariable analysis revealed
that preoperative sclerotherapy, intraoperative drain
placement, advanced age ([60 years), and weight loss at
presentation were associated with the development of
complications (Table 4). Although it is most likely that
multiple factors contributed to the development of com-
plications, drains may increase the risk of intraabdominal
abscesses and pneumonia when placed in abdominal
cavities for a long time. Similarly, if the drain exits the
skin in close proximity to the wound, the chance of
postoperative wound infection would increase signifi-
cantly. Preoperative sclerotherapy may help to safeguard
against upper GI bleed.
Pathology
Tumor histology results of 68 samples have shown that
there were 18% well, 53% moderately, and 29% poorly
Table 1 Comparison of the
clinical data of 116 HCC with
PVTT, divided into 2 time-
period cohorts
MELD model for end-stage liver
disease
a The data are expressed as the
mean value ± standard
deviation; values in bracket are
the corresponding percentage;
The P values are included in the
bracket; NS indicates that it is
not statistically significant
b The data were collected on
admission
c The data were collected 1 or
2 days prior to the operation
d The data were collected after
operation
Variables TP1
[N = 51, (%)]a
TP2
[N = 65, (%)]
Total
(P values)
Age (years) 45 ± 13 44 ± 9 44 ± 11 (NS)
Sex (NS)
Men 43 (84.3) 54 (88.5)
Women 8 (15.7) 11 (11.5)
HBsAg (NS)
Positive 44 (86.3) 54 (83.1)
Negative 7 (13.7) 11 (16.9)
HCV (NS)
Positive 6 (11.8) 9 (13.8)
Negative 45 (88.2) 56 (86.2)
ICG-R15c 14.8 ± 7.6 16.1 ± 7.9 15.6 ± 6.9 (NS)
Liver cirrhosisd (NS)
Present 36 (70.6) 47 (72.3)
Absent 15 (29.4) 18 (27.7)
CHILD-PUGH-scorec 8 ± 5 9 ± 4 (NS)
esophageal varicesb (NS)
Yes 9 (17.6) 17 (26.2)
No 42 (82.4) 48 (73.8)
MELD scoreb 27.89 ± 1.17 29.03 ± 0.81 (NS)
AFP (ng/ml)b 21,073 ± 80,830 19,832 ± 79,850 (NS)
Serum albumin (g/l)c 35.7 ± 4.9 35.8 ± 3.7 (NS)
Serum bilirubin obtained on admission (lmol/l)b 56.4 ± 62.9 57.6 ± 60.9 (NS)
Serum bilirubin obtained 1–2 days prior to
surgeries(lmol/l)c
15.6 ± 13.4 16.7 ± 11.6 (NS)
No. of tumors (0.048)
Solitary 43 (84.3) 42 (64.6)
Multiple 8 (15.7) 23 (35.4)
Ascitesb (NS)
Present 10 (19.6) 13 (20.0)
Absent 41 (80.4) 52 (80.0)
Hepatic vein invasionb (NS)
Negative 43 (84.3) 50 (76.9)
Positive 8 (15.7) 15 (23.1)
Neo-adjuvant therapy 9 31 (\0.001)
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differentiated tumors. The distribution of the levels of
the PVTT (Vp) was: Vp1 (22%), Vp2 (50%), Vp3
(20.6%), and Vp4 (7.4%). It should be noted that the
necrosis of HCC and PVTT was detected in patients
undergone neo-adjuvant therapy. There was no statisti-
cally significant difference in the classification of Vp by
CT preoperatively and the pathological assessment of Vp
postoperatively in all 68 patients who had undergone
resections.
Survival analysis
Figures 2, 3, and 4 compare the survival analyses results
between two TPs. Patients from TP2 had better overall
survival when comparing to those from TP1 (P \ 0.001)
(Fig. 2). One-, 3-year survival in TP1 was 31, 7% and 54,
34% in TP2, respectively. Median survival was 9 months
in TP1 and 15 months in TP2. Patients in both time-periods
had improved survival with (R0 and R1) surgical resection
(P \ 0.02 in TP1; P \ 0.001 in TP2 (Fig. 3a, b). Median
survival in TP1 for those undergone hepatic resection and
thrombectomy and those not having surgical resection was
21 months and 6 months, respectively (P \ 0.001). Simi-
larly, median survival was 36 months versus 7 months in
TP2 (P \ 0.001). Analyses also showed that patients in
TP2 had improved survival, when comparing the corre-
sponding Vps to that in TP1. Differences in survival by Vp
in each time-period were significant (P value TP1 \ 0.001,
TP2 \ 0.001; Fig. 4a, b). A multivariate analysis of factors
revealed that only those patients undergoing liver resection
combined with thrombectomy, chemotherapy, and Vp1-3
manifested a statistically significant improvement in
overall survival (Table 5).
A description of the 11 long-term survivors was pre-
sented in Table 6. All patients received radical resection
and chemotherapy. Ten patients suffered recurrence (mean
time to recurrence, 13.3 months). The most common site
of tumor recurrence was in the remnant liver. Treatment of
HCC recurrence was based on the site and pattern of
recurrence and the residual liver function. TACE, radio-
frequency ablation (RFA), and percutaneous ethanol
injection therapy (PEIT) were used for recurrent HCC.
Discussion
The management of HCC with PVTT still remained a
major challenge in surgery. Barcelona Clinic Liver Cancer
staging system proposed that patients with HCC and PVTT
were eligible for only palliative or investigational treat-
ments, but not for surgical intervention (Lin and Lu 1996;
Minagawa et al. 2001). However, the nonsurgical man-
agement of HCC with PVTT, including systemic chemo-
therapy and transarterial chemoembolization, was
associated with a dismal outcome of 1-year survival rate
between 7 and 18% (Okada et al. 1992; Raoul et al. 1994).
On the other hand, 1-, 2-, and 3-year survival rates as high
as 52.2, 23.2, and 11.6% had been reported in patients
undergone radical resection including hepatectomy and
thrombectomy, which was originally conducted to prevent
potential tumor rupture and esophageal variceal bleeding
(Yamaoka et al. 1992). Ohkubo et al (2000) and Masami
et al (2001) had also reported similar outcomes with
Fig. 1 Comparison of the distribution of Vps of disease at presen-
tation between two time-periods












Left hemihepatectomy 2 10







Type of PVTT removal 68 (\0.04)
Liver resection alone 16 27
Removal via PV stump 4 15
Removal via main trunk 1 5




Right adrenal gland resection 0 8
Splenectomy 0 2
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aggressive therapies. These results led to a reappraisal of
our aggressive approach to HCC patients with PVTT at the
turn of the century. In this paper, we compared the
aggressive management and survival outcomes of 2 distinct
approaches applied to this disease over the past 10 years.
Our results have shown that both the overall survival and
Table 3 Comparison of surgical and postoperative data of 68 HCC with PVTT
Variables TP1 (N = 21) TP2 (N = 47) Total (P values)
Average overall operative time (min) 167 14 155 (NS)
Average intraoperative blood loss (ml) 1,210 1,310 1,270 (NS)
Required blood transfusion 2 4 6 (NS)
Average occlusion time of the hepatic inflow (min) 11 12.5 11.8 (NS)
Adjuvant therapy 9 43 (\0.001)
Operative mortality 4.8% 4.3% 4.4% (NS)
Postoperative complication 42.9% 44.7% 45.6% (NS)
Mean length of stay (days) 12.7 9.8 10.7 (NS)
NS not significant
Table 4 Factors predictive of complications following surgery for HCC with PVTT: multivariate analysis
Covariates P value OR 95% CI
Time-period (1, 2) 0.96
Preoperative TACE (yes, no) 0.90
Combined organ resection (yes, no) 0.81
Sex (male, female) 0.70
Estimated blood loss (\1,000 ml, [1,000 ml) 0.61
Ascites (yes, no) 0.55
Operating time (\ 2 h, [2 h) 0.27
Drain (yes, no) 0.001 79.13 6.53–1,040
Preoperative sclerotherapy (yes, no) 0.002 61.73 4.42–750
Age (\60, [60 years) 0.027 18.63 2.86–196
Weight loss at presentation (yes, no) 0.045 11.50 1.34–135
Fig. 2 Comparison of overall
survival between 2 time-
periods: Kaplan–Meier curve
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the median 1-, 3-year survivals of all patients in TP2 were
significantly greater than that in TP1, despite the fact that
patients in TP2 had a larger proportion of multiple of
tumors and higher Vp disease.
Current study provided solid evidence that radical
resections could not only be performed safely with minimal
mortality (4.4%) but greatly increase patients’ 1-, 3-year
postoperative survival rates. It was worth pointing out here
that multivariate analyses had ruled out the radical resec-
tion as the contribution factor to the high postoperative
complications rate (45.6%). Multivariate analyses demon-
strated that the most important factor determining long-
term survival was liver resection with thrombectomy
(P \ 0.001). Surgical procedure was the only modality that
had the potential to completely remove the gross tumor
from the liver parenchyma and portal vein as well as
minimize residual tumor burden (Llovet et al. 1999b). The
benefits of tumor and thrombus resection en bloc or hep-
atectomy plus thrombectomy could be summarized as
follows: (1) decrease in portal vein pressure and prevention
of intractable ascites and esophageal varices bleeding; (2)
recovery of blood flow of portal vein and improvement of
liver function; (3) reducing the tumor burden and increas-
ing the efficacy of postoperative multimodality treatments
such as TACE, PVI, and HAI; and (4) improvement of
quality of life and survival rate of the patients (Tazawa
Fig. 3 Effect of liver resection
combined with thrombectomy
on patients’ survival in TP1 (a)
and TP2 (b)
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et al. 2001; Inoue et al. 2004). Therefore, surgical resection
was an effective therapy that could help to improve the
survival for HCC patients with PVTT.
Cox’s multivariate analysis showed that the level of the
PVTT (Vp) was an independent survival predictor for HCC
patients with PVTT. The postoperative prognosis of
patients varied with the different level of Vp (Chen et al.
2006). The 1- and 3-year survival rates for patients with
Vp1-3 and Vp4 were 52.1, 16.0%, and 33.1, 0%, respec-
tively. All patients with Vp4 died from recurrent HCC
within 400 days after surgery, while some patients with
Vp1, 2, or 3 obtained longer survival. These data suggests
that patients without Vp4 are encouraged to undergo sur-
gery in order to obtain longer survival. On the other hand,
surgery is not recommended to be the first choice of
treatment for patients with Vp4 unless it is an emergent
case with impending rupture of esophagogastric varices
due to portal hypertension or acute liver failure caused by
PVTT (Llovet et al. 1999a). Resection in such patients
should be re-evaluated when more effective adjuvant
treatments are available. It should be noted that most
recently, liver transplantation has been recommended to be
an alternative therapeutic for patients with HCC and PVTT
(Xu et al. 2004; Sotiropoulos et al. 2008). Giving the fact
Fig. 4 Comparison of patients’
survival between Vps in TP1 (a)
and TP2 (b)
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that current liver transplantation is associated with high
recurrence rate, high treatment cost and serious shortage of
organ donors, HCC patients with PVTT, especially those
with Vp3–4, were not recommended to undergo liver
transplantation (Van Thiel et al. 1998; Fan et al. 2000;
Iwatsuki et al. 2000; Frilling et al. 2001).
The results from current study also showed that sur-
gical removal of the main tumor and PVTT, combining
with the neo- and/or adjuvant therapy, significantly
improved the survival of HCC patients with PVTT. The
pre- and/or postoperative chemotherapy was more fre-
quently received in TP2 than in TP1, which in part
contributed to improve the survival of patients in TP2. It
was reported that neo-adjuvant therapy could prevent
the growth of HCC into the portal vein and was effec-
tive in the regression of portal thrombus (Chung et al.
1995; Vetter et al. 1991). IFN-a had a synergistic effect
with 5-FU and was able to enhance the antitumoral
efficacy of chemotherapy (Oie et al. 2006; Koike et al.
2006). Accumulation of iodized oil in PVTT, not only
in HCC nodules, was seen in many patients, and
necrosis of PVTT was detected by pathologic exami-
nation (Minagawa et al. 2001). Because hepatic artery
supply fed both the HCC and the PVTT, and the
residual microscopic tumor and micrometastases could
be existed in liver, adjuvant therapy had been used after
liver resection combined with PVTT removal (Liang
et al. 2008; Peng et al. 2009). This approach has been
proven to be able to prolong patient’s survival (Fan
et al. 2003).
In summary, a remarkable improvement has been
achieved in the outcome of the treatment of patients with
HCC and PVTT over the past 5 years, after a shift to a
more aggressive approach. Multivariate examination
accounting for the time-period in which treatment per-
formed revealed that the most important factor determining
long-term survival was whether the patient underwent an
aggressive liver resection with thrombectomy and chemo-
therapy. On the other hand, even in the most recent time-
period, a maximal 3-year survival rate of only 34% has
been achieved. Therefore, it is essential that novel adjuvant
therapies should be developed and evaluated for these
patients.






P value HR 95% CI
Radical resection 0.0001 0.001 0.28 0.14–0.59
Vp (Vp1–3, Vp4) 0.008 0.002 2.34 1.29–5.00
Chemotherapy 0.002 0.05 2.29 0.99–4.72
Weight loss at presentation 0.0001 0.28 1.60 0.82–3.17
No. of tumors 0.003 0.54 0.77 0.61–1.23
Time-period 0.001 0.61 0.81 0.38–1.54
ICG-R15 0.03 0.87 0.93 0.47–1.87





Estimated blood loss 0.93
Preoperative sclerotherapy 0.81
AFP (ng/ml) (B25, [25) 0.87
HBsAg 0.76
Age (\60, [60) 0.91
Table 6 Actual long-term survivors: Following surgery for HCC with PVTT
TP Age/sex Vp Surgical resection Adjuvant therapy Survival/status
TP1 48 years/M Vp1 Yes Pre- and postoperative TACE 4 years 10 months DOD
TP1 56 years/M Vp2 Yes Preoperative TACE 5 years 9 months DOD
TP1 59 years/M Vp3 Yes Pre- and postoperative TACE 4 years 2 months DOD
TP2 42 years/M Vp3 Yes Preoperative TACE 3 years 6 months NED
TP2 64 years/F Vp3 Yes Postoperative TACE 4 years 1 months DOD
TP2 43 years/M Vp2 Yes Preoperative TACE 4 years 9 months DOD
TP2 57 years/M Vp3 Yes Preoperative TACE 8 years 5 months NED
TP2 65 years/M Vp1 Yes Preoperative TACE 5 years 9 months NED
TP2 57 years/M Vp3 Yes Pre- and postoperative TACE 3 years 7 months DOD
TP2 33 years/M Vp1 Yes Postoperative TACE 4 years 1 months DOD
TP2 45 years/M Vp2 Yes Preoperative TACE 7 years 3 months NED
TACE transcatheter hepatic arterial chemoembolization, DOD dead of disease, NED no evidence of disease
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